A Phase 4 interventional study of salmeterol xinafoate/fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Terminated at 132 sites in Canada. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-03-21.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.
Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 5th largest by enrollment, is one of 7 that started in 2004, is one of 26 in phase 4, and was the 9th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →
Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 680 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 128 across the 46 interventional studies. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 19th largest by enrollment of the 238 interventional ones that give a count, is one of 10 that started in 2004, is one of 53 in phase 4, and was the 10th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing Salmeterol Xinafoate in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will compare patients treated with a marketed medication and those who continue with their usual care to assess the proportion of patients achieving well controlled asthma after 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Salmeterol Xinafoate · Fluticasone
Percentage of patients achieving well-controlled asthma at the end of the treatment period.
Percentage of patients achieving total asthma control as defined by the Canadian Asthma consensus guidelines at the end of the treatment period.
Showing the first 100 of 132 sites. Choose a country and city above to see the rest.
The record gives a start of Nov 2004 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone